GSK2894512 is a novel anti-inflammatory agent that is currently under development for the
topical treatment of atopic dermatitis and chronic plaque psoriasis. This study will be a
Phase I, single-center, randomized, partial-blinded (evaluator blinded) study which consists
of two parts (Part 1 and 2). Part 1 of this study will assess skin irritation following a
single application of GSK2894512 cream at 2 concentrations (e.g. 0.5% and 1%) and placebo by
simple-patch test and photo-patch test under semi-occlusive conditions in 20 healthy Japanese
volunteers. Part 2 of this study will assess skin irritation following repeat application at
0.5% and 1% of GSK2894512 cream and placebo for 7 days under non-occlusive condition in 6
healthy Japanese volunteers. The study will have Screening visit which will occur within 30
days from the Day 1 visit of each part. Eligible subjects will be able to participate either
of Part 1 or Part 2. Subjects will visit the site on Day -1, and hospitalized until the end
of all assessments on Day 4 (Part 1) or Day 7 (Part 2). Subjects will re-visit the site on
Day 8 (Part 1) or Day 15 (Part 2) for follow-up assessments. This study will be the first to
evaluate the safety, tolerability and pharmacokinetics of GSK2894512 cream after single and
repeat application in Japanese subjects. Results from this study will enable further clinical
investigation in the Japanese population.